Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q9H3S3
UPID:
TMPS5_HUMAN
Alternative names:
Spinesin
Alternative UPACC:
Q9H3S3
Background:
Transmembrane protease serine 5, also known as Spinesin, is a protein that may play a crucial role in hearing. This protein is characterized by its transmembrane nature and serine protease activity, suggesting a specific function in cellular processes.
Therapeutic significance:
Understanding the role of Transmembrane protease serine 5 could open doors to potential therapeutic strategies. Its involvement in auditory functions hints at the possibility of developing treatments for hearing impairments.